Intellia Therapeutics
(NASDAQ) NTLA
Intellia Therapeutics Financials at a Glance
Market Cap
$2.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$66.09M
Net Income (TTM)
-$394.60M
EPS (TTM)
-$3.53
P/E Ratio
-4.97
Dividend
$0.00
Beta (Volatility)
1.95 (High)
Dividend
$0.00
Beta (Volatility)
1.95 (High)
Price
$17.88
Volume
146,108
Open
$17.47
Price
$17.88
Volume
146,108
Open
$17.47
Previous Close
$17.88
Daily Range
$16.22 - $18.08
52-Week Range
$7.95 - $28.25
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.95 (High)
Price
$17.88
Volume
146,108
Open
$17.47
Previous Close
$17.88
Daily Range
$16.22 - $18.08
52-Week Range
$7.95 - $28.25
Estimated Earnings Date
Aug 6, 2026
NTLA News
NTLA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Intellia Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
377
CEO
John M. Leonard, MD
Website
www.intelliatx.comHeadquarters
Cambridge, MA 02139, US
NTLA Financials
Key Financial Metrics (TTM)
Gross Margin
-153.74%
Operating Margin
-636.56%
Net Income Margin
-597.04%
Return on Equity
-57.27%
Return on Capital
-57.67%
Return on Assets
-52.00%
Earnings Yield
-20.12%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
139.72M
Volume
146.11K
Avg. Volume
6.56M
Financials (TTM)
Gross Profit
-$101.61M
Operating Income
-$420.72M
EBITDA
-$384.61M
Operating Cash Flow
-$363.15M
Capital Expenditure
-$473.00K
Free Cash Flow
-$363.63M
Cash & ST Invst.
$375.99M
Total Debt
$80.49M
Intellia Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$15.05M
-9.5%
Gross Profit
$12.85M
-22.7%
Gross Margin
85.37%
N/A
Market Cap
$2.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$6.09M
N/A
Employees
403
N/A
Net Income
-$96.23M
+15.8%
EBITDA
-$94.03M
+15.9%
Quarterly Fundamentals
Total Cash
$375.99M
-25.4%
Total Debt
$80.49M
-32.5%
Accounts Receivable
$9.13M
-13.1%
Inventory
$0.00
N/A
Long Term Debt
$61.40M
-23.7%
Short Term Debt
$19.10M
-50.7%
Return on Assets
-52.00%
N/A
Return on Invested Capital
-61.66%
N/A
Free Cash Flow
-$117.43M
+21.5%
Operating Cash Flow
-$117.35M
+21.2%